Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUNLUN: durvalumab with definitive chemoradiation in unresectable locally advanced esophageal squamous cell carcinoma
jRCT2061200025Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Durvalumab + definitive chemoradiation therapy with Placebo + definitive chemoradiation therapy (2 arms). Primary endpoint: Progression-free survival. Started Nov 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2061200025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200025.